Legend Biotech Corporation
(NASDAQ: LEGN)
|
8:00 PM UTC, 09/27/24 | |||
---|---|---|---|---|
Last: $49.27 | Change: +2.42 | %Change: +5.17% | Volume: 984,055 |
Open: | $ 47.32 | Volume: | 984,055 | |
---|---|---|---|---|
High: | $ 49.87 | Yield(%) | 0.00 | |
Low: | $ 47.00 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 8.58B | |
EPS ($) | -1.57 | Shares Out: | 183.17M |
% Price Change (last 4 weeks): | -17.39 |
---|---|
% Price Change (last 13 weeks): | 4.90 |
% Price Change (last 26 weeks): | -16.47 |
% Price Change (last 52 weeks): | -30.40 |
% Price Change (year to date): | -22.14 |
Return on Equity (%): | -51.94 |
---|---|
Return on Assets (%): | -32.60 |
Return on Invested Capital (%): | -131.18 |
Gross Profit Margin (%): | 42.25 |
---|---|
Net Profit Margin (%): | -181.75 |
Operating Profit Margin (%): | -155.09 |
50-day Moving Average: | $54.20 |
---|---|
200-day Moving Average: | $53.66 |
Avg. Daily Vol. (last 50 days): | 815,913 |
Avg. Daily Vol. (last 200 days): | 1,012,969 |
52-wk high: | $70.78 |
52-wk low: | $38.60 |
Bid: | $49.00 |
Ask: | $50.00 |
Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.
|
Legend Biotech Corporation
2101 Cottontail Lane Somerset NJ 08873 Phone: 1.737.317.5050 Fax: n/a http://www.legendbiotech.com |
Earnings (1year) ($): | -1.57 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 6.88 |
Cash Flow ($): | -2.74 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 37.16 |
Price/Book (x): | 8.75 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 6.83 |
---|---|
Current Ratio (x): | 6.92 |
LT Debt/Equity (x): | 26.01 |
Total Debt/Equity (x): | 26.26 |